Vor Biopharma (NASDAQ:VOR) Shares Up 9.3% – Here’s Why

Vor Biopharma Inc. (NASDAQ:VOR) shares rose 9.3% during trading on Thursday . The company traded as high as $14.73 and last traded at $14.6950. Approximately 260,078 shares traded hands during trading, a decline of 73% from the average daily volume of 965,606 shares. The stock had previously closed at $13.44.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Wells Fargo & Company assumed coverage on Vor Biopharma in a research report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price target for the company. Wedbush lifted their price target on Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. HC Wainwright reiterated a “buy” rating and issued a $31.00 price target on shares of Vor Biopharma in a research report on Monday, May 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $42.25.

Vor Biopharma Stock Performance

The company has a 50-day moving average of $15.24 and a 200 day moving average of $13.69.

Vor Biopharma (NASDAQ:VOR) last posted its earnings results on Monday, March 30th. The company reported $307.61 EPS for the quarter. As a group, equities research analysts predict that Vor Biopharma Inc. will post -2.51 EPS for the current year.

Insider Transactions at Vor Biopharma

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 165,150 shares of Vor Biopharma stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the completion of the sale, the director owned 2,402,095 shares of the company’s stock, valued at $37,881,038.15. The trade was a 6.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 3,002,903 shares of company stock worth $49,412,176 over the last three months. Insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Vor Biopharma

Several hedge funds have recently added to or reduced their stakes in VOR. China Universal Asset Management Co. Ltd. bought a new position in Vor Biopharma during the 4th quarter valued at approximately $36,000. Bank of America Corp DE raised its position in Vor Biopharma by 679.3% during the 3rd quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock valued at $232,000 after purchasing an additional 4,144 shares during the last quarter. Squarepoint Ops LLC bought a new position in Vor Biopharma during the 3rd quarter valued at approximately $230,000. BNP Paribas Financial Markets raised its position in Vor Biopharma by 497.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after purchasing an additional 5,058 shares during the last quarter. Finally, Bridgeway Capital Management LLC bought a new position in Vor Biopharma during the 3rd quarter valued at approximately $304,000. Institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).